John Libbey Eurotext

European Journal of Dermatology

MENU

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study Volume 28, numéro 6, November-December 2018

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3

Tableaux

Auteurs
1 Karolinska Institutet, Solma,
17176 Stockholm,
Sweden
2 Genentech, Inc.,
1 DNA Way,
South San Francisco,
California
94080 USA
3 Aix-Marseille University,
Timone Hospital,
264 rue Saint-Pierre,
13385 Marseille cedex 05,
France
4 Medical University of Vienna,
Währinger Gürtel 18-20,
1090 Vienna,
Austria
5 Nantes University,
place Alexis-Ricordeau,
44093 Nantes cedex 01,
France
6 University of Lille 2,
Lille Regional University Hospital,
2 avenue Oscar-Lambret,
59037 Lille cedex,
France
7 Istituto Nazionale Tumori Fondazione G. Pascale,
Via Mariano Semmola,
80131 Naples,
Italy
8 Fondazione IRCCS Istituto Tumori,
Via Giacomo Venezian 1,
20133 Milan,
Italy
9 University Hospital of Bordeaux,
1, rue Jean-Burguet,
33075 Bordeaux,
France
10 Centre Hospitalier Lyon Sud,
69495 Pierre-Bénite cedex,
France
11 Paul-Sabatier University and Toulouse Cancer University Institute,
170 avenue de Casselardit,
31059 Toulouse,
France
12 University Hospital of Montpellier,
80, avenue Augustin-Fliche,
34090 Montpellier,
France
13 University Hospital of Zurich,
Gloriastr. 31,
8091 Zurich,
Switzerland
14 Cambridge University Hospitals,
NHS Foundation Trust,
Addenbrookes Hospital,
Hills Road,
Cambridge CB2 2OQ, UK
15 Western University,
London Regional Cancer Program,
790 Commissioners Road,
East London NGA 4L6,
Ontario,
Canada
16 Roche Products Ltd,
6 Falcon Way,
Shire Park,
Welwyn Garden City AL7 1TW, UK
17 University Paris 7 and Hôpital Saint-Louis,
1 avenue Claude-Vellefaux,
75475, Paris, France
18 University Hospital Schleswig-Holstein and University of Kiel,
Rosalind-Franklin-Str. 7,
D-24105 Kiel,
Germany
* Reprints
  • Mots-clés : basal cell carcinoma, Hedgehog pathway inhibitor, HRQoL, locally advanced, STEVIE, vismodegib
  • DOI : 10.1684/ejd.2018.3448
  • Page(s) : 775-83
  • Année de parution : 2018

Background

Health-related quality of life (HRQoL) data are limited in patients with advanced basal cell carcinoma.